CommercialCoverageMedium impact
08.00.75r, Erythropoiesis-Stimulating Agents (ESAs)
Independence Blue Cross·Nephrology, Oncology, Hematology +1 more·Medical Policy
Effective date
Jun 15, 2026
We identified it
Jun 19, 2026
Summary
The IBX commercial medical policy for Erythropoiesis-Stimulating Agents (ESAs) has been updated with changes to medical necessity criteria and medical coding requirements. This affects billing and coverage determination for ESA medications used to treat anemia.
Action Required
Before June 15, 2026: Billing team must review updated medical necessity criteria for ESA medications and update prior authorization documentation requirements. Verify any coding changes for ESA administration and update billing system rules accordingly. Notify providers of new documentation requirements to prevent claim denials.